Dr Yuan and colleagues from China investigated the efficacy of antepartum administration of 3 doses of Hepatitis B immunoglobulin.
The research team evaluated 250 pregnant women who were seropositive for Hepatitis B e antigen.
The team randomly divided 117 to in Group 1 as controls and 133 in Group2 as cases.
The team had subjects in the study group receive Hepatitis B immunoglobulin 400 IU intramuscularly once a month at 3, 2, and 1 month before delivery.
Subjects in the control group received no antepartum treatment.
|Postnatal immunoprophylaxis efficacy rates did not differ between groups|
|Journal of Viral Hepatitis|
All neonates received passive-active immunization after birth.
The researchers measured maternal Hepatitis B virus markers, and Hepatitis B surface antigen Hepatitis B e antigen titres.
Hepatitis B virus deoxyribonucleic acid levels were measured at week 28 of gestation, before the antepartum treatment, and at labor.
The neonatal serum Hepatitis B virus markers were detected at birth and at 12 months after birth.
The team found no side-effects in any of the women or their neonates.
No statistical differences were seen between the maternal Hepatitis B e antigen and Hepatitis B virus deoxyribonucleic acid levels of either group at labour.
The researchers observed no difference between the groups in the protective efficacy rates of postnatal immunoprophylaxis at 12 months after birth.
Dr Yuan's team concluded, “Antepartum administration of 3 doses of Hepatitis B immunoglobulin for the Hepatitis B e antigen -positive women is inefficacious.”